U.S. Contraceptives Drugs And Devices Market, By Product Type - Insights, Opportunity Analysis, and Industry Forecast till 2024

Contraceptives are birth spacing products that aid in avoiding unplanned pregnancy. There are five widely used contraceptive methods, namely sterilization, hormonal method, barrier method, emergency contraception, and intrauterine method. Sterilization is the most common method implemented globally. While there are a plethora of female contraceptives available in the market, companies and a few University researchers are trying to introduce male contraceptive methods. Women contraceptive methods include vaginal rings, diaphragms, female condoms, oral pills, and intra-uterine devices (IUD). Selecting the most appropriate method is critical to avoid undesired side effects. The use of contraceptives can avoid 60% of maternal deaths and 57% of child deaths worldwide, as opined by the World Health Organization (WHO) in 2014. Therefore, various family planning initiatives have been introduced by governmental and non-governmental agencies in order to create awareness about prevention of unplanned pregnancy.

Market Dynamics

Companies present in the contraceptives market prefer marketing oral contraceptive pills to churn out considerable and constant revenues compared to one-time revenue generated through long-acting contraceptives. Moreover, there is heavy promotion of oral pills compared to the long acting contraceptives such as IUD, and implant. This has kept the consumers away from the real benefits of long acting contraceptives over the oral pills. This is the reason that oral pills dominate the U.S. contraceptive drugs and devices market. The oral pills market is projected to experience the entry of generics with patent expirations nearing in the forecast period.

However, demand for advanced contraceptive options such as IUD, injectables, implants and diaphragms is observed to be high globally. This is owing to growing awareness among the populace, availability of reimbursement and growing demand for long term contraceptive methods. Government promotes the use of IUD and implants i.e. long-acting contraceptives for better therapeutic effect and safety. Also, reimbursement schemes are made attractive for consumers to opt for these contraceptive methods.

Market Taxonomy

This report segments the U.S. contraceptives drugs and devices market on the basis of product type and geography. On the basis of product type, the U.S. contraceptives drugs and devices market is segmented into drug and devices. Drugs are further sub-segmented into oral pills, injectables, and topical contraceptives. The contraceptive devices segment is further sub-segmented into male contraceptives devices and female contraceptives devices. Female contraceptives devices include female condoms, contraceptive diaphragms, contraceptive sponges, and contraceptive vaginal rings. Intrauterine devices, and subdermal contraceptive implants.

Key features of the study:

• This report provides in-depth analysis of the U.S. contraceptives drugs and devices and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the U.S. contraceptives drugs and devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Reckitt Benckiser Plc, Pfizer, Inc., Bayer AG, Mayer Laboratories, Inc., The Female Health Company, Cooper Surgical, Inc., Allergan plc, Cipla Limited, and Merck & Co. Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, market expansion, and marketing tactics
• The U.S. contraceptives drugs and devices market report caters to various stakeholders in this industry, including investors, drug and device manufacturers, distributors and suppliers for contraceptives drugs and devices, government organizations, research and consulting firms, new entrants, and financial analysts
• Various strategy matrices used in analyzing the contraceptives drugs and devices market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

• U.S. Contraceptives Drugs And Devices Market, By Product Type:
• Contraceptive Drugs
• Oral Contraceptive Pills
• Contraceptive Injectables
• Topical Contraceptives
• Contraceptive Devices
• Male Contraceptive Devices
• Condoms
• Female Contraceptive Devices
• Female Condoms
• Contraceptive Diaphragms
• Contraceptive Sponges
• Contraceptive Vaginal Rings
• Intrauterine Devices
• Hormonal
• Copper-T
• Subdermal Contraceptive Implants
• Company Profiles
• Teva Pharmaceutical Industries Ltd.*
• Company Overview
• Product Portfolio
• Financial Performance
• Key Strategies
• Recent Developments
• Future Plans
• Church & Dwight Co. Inc.
• Reckitt Benckiser Plc
• Pfizer, Inc.
• Bayer AG
• Mayer Laboratories, Inc.
• The Female Health Company
• Cooper Surgical, Inc.
• Allergan Plc
• Cipla Limited
• Merck & Co. Inc.

“*” marked represents similar segmentation in other categories in the respective section.